Protagonist Therapeutics Inc (PTGX)
Debt-to-equity ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 336,677 | 215,608 | 300,021 | 279,606 | 79,964 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $336,677K
= 0.00
Protagonist Therapeutics Inc has consistently maintained a debt-to-equity ratio of 0.00 for the past five years, indicating that the company has not utilized debt financing to fund its operations or investment activities. This suggests that the company has been primarily relying on equity financing to support its growth and capital expenditure needs. A debt-to-equity ratio of 0.00 typically signifies that the company's financial structure is conservative and that it is not exposed to the risks associated with high levels of debt. It also demonstrates strong financial stability and a healthy balance sheet. Overall, Protagonist Therapeutics Inc's consistent low debt-to-equity ratio indicates a prudent financial management strategy focused on minimizing debt obligations and maintaining a strong equity base.
Peer comparison
Dec 31, 2023